We thank our speakers Uli Hacksell, Medivir, Martin Bonde, Vaccibody and Per Andersson,Xspray and a special thank you to Uli for sharing some of his key learnings from a long and successful career in life science, pointing to the importance of uncomplicated design of clinical trials, strong IP and understanding of the regulatory path – and of course, above all, funding!

The afternoon was wrapped up with a panel discussion with interesting contributions from, among other, Johan Christenson, Healthcap and Charlotte Edenius, Gesynta.

Want do invest in LifeScience? Arctic Aurora LifeScience is open for large and small investors investing in lifescience and biotech companies primarily in Europe and the United States. 


Arctic Aurora LifeScience is an equity fund investing in global biotechnology and pharmaceutical companies. The fund is run by former portfolio manager in the Swedish Governmental Pension Fund AP3, Ulrica Bjerke, as well as Dr. Torbjørn Bjerke, both with 20 years of experience from the market. Arctic Aurora LifeScience was launched in May 2016 with both hedged and un-hedged share classes.

Past performance in Arctic Aurora LifeScience is no guarantee for future returns. Future returns depend on the market, fund manager skill, fund risk level, costs, among others. Performance in the fund may at times be negative and may for this fund vary considerably within periods.